SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the ...
SAN FRANCISCO, Feb 11 (Reuters) - Among early users of Novo Nordisk's (NOVOb.CO), opens new tab new Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new nationwide ...
Reigning world champion Lando Norris finished the first public day of Formula 1 testing in 2026 fastest at the Bahrain International Circuit. The McLaren driver set a benchmark time of a 1:34.669s to ...
The widely used glycated haemoglobin (HbA1c) test may not accurately reflect blood glucose levels for millions of Indians, according to a new evidence-based viewpoint published online in the Lancet ...
2026 MotoGP track action begins with the traditional three-day Sepang Shakedown test, which runs from Thursday to Saturday (January 29-31). The Shakedown will be the first chance to see the latest ...
UC San Diego Health researchers develop a simple test to detect pulmonary arterial hypertension before it leads to heart failure. LA JOLLA, Calif. (KGTV) - New research from UC San Diego Health shows ...
People who stop taking GLP-1 drugs such as Ozempic and Wegovy for weight loss are projected to regain their shed pounds within about 1½ years, a review of existing research has found. The paper also ...
A potential cure for type 1 diabetes has been identified by scientists in a new mouse study. In an animal study, researchers at Stanford School of Medicine discovered that resetting the immune system ...
Laborie Announces First Procedures in ENDURE 1 Study with the Optilume® Ureteric Drug-Coated Balloon
Landmark procedures launch the ENDURE 1 clinical study evaluating Optilume's safety and feasibility as a new minimally invasive option for patients with benign ureteric strictures. PORTSMOUTH, N.H., ...
In the fourth iOS 26.1 beta, Apple added a "Tinted" option that reduces the translucency of Liquid Glass for those who prefer a more opaque look. I saw some comments wondering whether the setting ...
Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, citing poor data and tough competition. Pfizer's last remaining GLP-1 agonist, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results